Agenus Inc. Stock News

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financial results before the market opens on Monday, November 10, 2025. The company also plans to host a stakeholder briefing webcast in late November to provide a corporate and clinical development update. ...

Agenus Inc. (NASDAQ:AGEN ) Shareholder/Analyst Call October 21, 2025 4:00 PM EDT Company Participants Stefanie Perna-Nacar - Chief Communications & Government Relations Officer Garo Armen - Founder, Executive Chairman & CEO Richard Goldberg - Chief Development Officer Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Conference Call Participants Michael S. Gordon Alex...

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new data from its botensilimab (BOT), a multifunctional, Fc-enhanced CTLA-4 antibody and balstilimab (BAL), a PD-1 inhibitor, combination demonstrating durable survival across multiple cancer types in late-stage patients who have limited treatment options. The re...

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #ESMO2025--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, will host a virtual Stakeholder Briefing on Tuesday, October 21, 2025, at 4:00 p.m. ET. The webcast will feature updates from leading experts on recent clinical progress and expanding international access for its immunotherapy combination botensilimab (BOT) and balstilimab ...

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite‑stable (MSS) metastatic colorectal cancer (mCRC) under France's compassionate access (Accès compassionnel, or AAC) framework. The Fre...

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the company will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. Dr. Richard Goldberg, Chief Development Officer, and Dr. Robin Taylor, Chief Commerc...

Agenus Inc. (NASDAQ:AGEN ) Virtual Stakeholder Briefing Conference Call August 27, 2025 8:30 AM ET Company Participants Garo H. Armen - Founder, Executive Chairman & CEO Jennifer S.

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced an update to its virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET which introduces a new virtual format to provide an engaging experience for attendees, along with an updated participation link. Stakeholder Webcast Participation Details NEW Audience Webcast Link ...